Otomagnetics, a University of Maryland College Park spin-out that is developing a non-invasive method to effectively deliver drugs and other therapeutic payloads to hard-to-reach targets in the body, to ear compartments, to the eye, and into the skin, announced today that it has named Abhita Batra, MS, MBA, as CEO.
Ms. Batra has served as Otomagnetics’ CBO since 2016. Previously, she was Vice President of Business Development and Marketing at Admac Group of Companies, where she managed a product portfolio of more than 150 generics. She is also the Co-Founder and former COO of Navya, a biotechnology company developing and commercializing PHF for the destruction of solid tumors.
Ms. Batra completed her Global MBA at UCLA Anderson and the National University of Singapore, and has a Master’s degree in Biotechnology with a specialization in Pharmaceutical Sciences from the University of Pennsylvania.
“I am excited to lead the organization and bring a change in the drug delivery landscape,” commented Ms. Batra, who is also the Founder and Managing Director of Advanced Biopharma Consulting (ABC), a strategic advisory firm that provides business development and commercialization services to life science companies. “I am confident and strongly believe that Otomagnetics’ patient-centric non-invasive magnetic drug delivery will offer a quality of life that patients deserve.”
“Abhita has extensive experience in starting and growing life sciences companies, and we are pleased to bring her as CEO of Otomagnetics,” commented Benjamin Shapiro, President and Co-Founder of Otomagnetics. “Abhita will lead Otomagnetics’ corporate strategy, business development, and day-to-day operations, and help commercialize the company’s magnetic drug delivery platform.”
Otomagnetics’ drug delivery platform combines a proprietary magnetic injector with bio-degradable magnetic particles that are composed solely out of materials approved by the FDA for injection into the body, which can essentially carry any therapy including drugs, proteins, or genes. The company has generated interest from multiple pharmaceutical firms, and earlier this year it was one of six startups selected by AngelMD to receive funding from a pool of more than 150 applicants.
For more information, visit http://otomagnetics.net.
Otomagnetics is developing a patient-centric non-invasive method to effectively deliver drugs and other therapeutic payloads to hard-to-reach targets in the body, to ear compartments, to the eye, and into the skin.